IL-28, IL-29 and their class II cytokine receptor IL-28R, Nature Immunology, vol.4, issue.1, pp.63-68, 2003. ,
DOI : 10.1038/ni873
IFN-??s mediate antiviral protection through a distinct class II cytokine receptor complex, Nature Immunology, vol.4, issue.1, pp.69-77, 2003. ,
DOI : 10.1038/ni875
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance, Nature, vol.18, issue.7262, pp.399-401, 2009. ,
DOI : 10.1038/nature08309
Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus, Gastroenterology, vol.139, issue.1, pp.120-129, 2010. ,
DOI : 10.1053/j.gastro.2010.04.013
An IL28B Polymorphism Determines Treatment Response of Hepatitis C Virus Genotype 2 or 3 Patients Who Do Not Achieve a Rapid Virologic Response, Gastroenterology, vol.139, issue.3, pp.821-827, 2010. ,
DOI : 10.1053/j.gastro.2010.05.079
Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing, Clinical Pharmacology & Therapeutics, vol.87, issue.6, pp.721-726, 2010. ,
DOI : 10.1097/00007890-200212150-00002
Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients12, Transplantation, vol.76, issue.8, pp.1233-1235, 2003. ,
DOI : 10.1097/01.TP.0000090753.99170.89
Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients, Gene, vol.512, issue.2, pp.226-257, 2013. ,
DOI : 10.1016/j.gene.2012.10.048
CYP3A5 Genotype Does Not Influence Everolimus In Vitro Metabolism and Clinical Pharmacokinetics in Renal Transplant Recipients, Transplantation, vol.91, issue.6, pp.652-658, 2011. ,
DOI : 10.1097/TP.0b013e31820ae4ac
URL : https://hal.archives-ouvertes.fr/inserm-00542366
The largest prospective warfarin-treated cohort supports genetic forecasting, Blood, vol.113, issue.4, pp.784-792, 2009. ,
DOI : 10.1182/blood-2008-04-149070
Estimation of the warfarin dose with clinical and pharmacogenetic data, N. Engl. J. Med, vol.360, issue.8, pp.753-764, 2009. ,
Genetic Determinants of Response to Warfarin During Initial Anticoagulation, Journal of Vascular Surgery, vol.47, issue.6, pp.999-1008, 2008. ,
DOI : 10.1016/j.jvs.2008.04.040
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications, The Lancet, vol.353, issue.9154, pp.717-719, 1999. ,
DOI : 10.1016/S0140-6736(98)04474-2
Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design, Pharmacogenomics, vol.10, issue.10, pp.1687-1695, 2009. ,
DOI : 10.2217/pgs.09.125
CYP3A5 Genotype Does Not Influence Everolimus In Vitro Metabolism and Clinical Pharmacokinetics in Renal Transplant Recipients, Transplantation, vol.91, issue.6, pp.652-658, 2011. ,
DOI : 10.1097/TP.0b013e31820ae4ac
URL : https://hal.archives-ouvertes.fr/inserm-00542366
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.col Ther, 2008. ,
Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2, Nature, vol.427, issue.6974, pp.537-541, 2004. ,
DOI : 10.1038/nature02214
Haplotypes on Transcriptional Regulation and Warfarin Dose, New England Journal of Medicine, vol.352, issue.22, pp.2285-2293, 2005. ,
DOI : 10.1056/NEJMoa044503
Identification of the gene for vitamin K epoxide reductase, Nature, vol.427, issue.6974, pp.541-544, 2004. ,
DOI : 10.1038/nature02254
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.col Ther, 2008. ,
Site-directed mutagenesis of coumarin-type anticoagulant-sensitive VKORC1: evidence that highly conserved amino acids define structural requirements for enzymatic activity and inhibition by warfarin, Thromb Haemost, 2005. ,
Preponderance of Thiopurine S-Methyltransferase Deficiency and Heterozygosity Among Patients Intolerant to Mercaptopurine or Azathioprine, Journal of Clinical Oncology, vol.19, issue.8, pp.2293-2301, 2001. ,
DOI : 10.1200/JCO.2001.19.8.2293
Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy, British Journal of Clinical Pharmacology, vol.66, issue.4, pp.575-84, 2011. ,
DOI : 10.1111/j.1365-2125.2010.03867.x
Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia, JAMA Mar, vol.23293, issue.12, pp.1485-1494, 2005. ,
Transporter Pharmacogenetics and Statin Toxicity, Clinical Pharmacology & Therapeutics, vol.278, issue.1, pp.130-133, 2010. ,
DOI : 10.1097/01.fpc.0000230422.50962.91
SLCO1B1 variants and statin-induced myopathy ? a genomewide study, N. Engl. J. Med, vol.359, issue.8, pp.789-799, 2008. ,
SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin, Clinical Pharmacology & Therapeutics, vol.80, issue.4, pp.356-366, 2006. ,
DOI : 10.1016/j.clpt.2006.06.010
The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy, Clinical Pharmacology & Therapeutics, vol.378, issue.1, pp.112-119 ,
DOI : 10.1038/clpt.2010.279
Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin, Clinical Pharmacology & Therapeutics, vol.382, issue.6, pp.726-733, 2007. ,
DOI : 10.1038/sj.clpt.6100220
Type de prélèvement : sang total sur tube EDTA (bouchon Violet) -Acheminement: délai maximum 48h à température ambiante, congelé si délai supérieur. -Consentement écrit signé du patient et du médecin prescripteur indispensable -Info cliniques : prescription médicale détaillée précisant le gène à génotyper ,
Prolonged Unconjugated Hyperbilirubinemia Associated With Breast Milk and Mutations of the Bilirubin Uridine Diphosphate- Glucuronosyltransferase Gene, Pediatrics, vol.106, issue.5, 2000. ,
DOI : 10.1542/peds.106.5.e59
Analysis of genes for bilirubin UDP-glucuronosyltransferase in Gilbert's syndrome. Lancet, Apr, vol.15345, issue.8955, pp.958-967, 1995. ,
Identification of a genetic alteration in the code for bilirubin UDP-glucuronosyltransferase in the UGT1 gene complex of a Crigler-Najjar type I patient., Journal of Clinical Investigation, vol.90, issue.1, pp.150-155, 1992. ,
DOI : 10.1172/JCI115829
Clinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancer. Onco Targets Ther, pp.1653-61, 2014. ,
The Role of UGT1A1*28 Polymorphism in the Pharmacodynamics and Pharmacokinetics of Irinotecan in Patients With Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.24, issue.19, pp.3061-3069, 2006. ,
DOI : 10.1200/JCO.2005.05.5400
Non response to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene, J Clin Psychopharmacol, 2004. ,
Dose-dependent pharmacokinetics of caffeine in humans: Relevance as a test of quantitative liver function, Clinical Pharmacology and Therapeutics, vol.47, issue.4, pp.516-524, 1990. ,
DOI : 10.1038/clpt.1990.66
Practical recommendations for pharmacogenomics-based prescription, ESF-UB Conference on Pharmacogenetics and Pharmacogenomics, pp.113-137, 2010. ,
DOI : 10.2217/pgs.10.147
The CYP2D6 Activity Score: Translating Genotype Information into a Qualitative Measure of Phenotype, Clinical Pharmacology & Therapeutics, vol.38, issue.2, pp.234-276, 2008. ,
DOI : 10.1038/sj.clpt.6100406
Breast Cancer Treatment Outcome With Adjuvant Tamoxifen Relative to Patient CYP2D6 and CYP2C19 Genotypes, Journal of Clinical Oncology, vol.25, issue.33, pp.5187-93, 2007. ,
DOI : 10.1200/JCO.2007.12.2705
Cytochrome P450 2D6*10 genotype affects the pharmacokinetics of dimemorfan in healthy Chinese subjects, European Journal of Drug Metabolism and Pharmacokinetics, vol.16, issue.914 ,
DOI : 10.1007/s13318-014-0221-x
Admissions to hospital caused by adverse drug reactions: cross sectional incidence study, BMJ, vol.320, issue.7241, p.1036, 2000. ,
DOI : 10.1136/bmj.320.7241.1036
Effets indésirables des médicaments: Incidence et risques, sur les hospitalisations liées à un effet indésirable médicamenteux, Coordination CRPV, vol.4, p.2012, 2007. ,
Genetic determinants of response to clopidogrel and cardiovascular events, N Engl J Med, 2009. ,
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer, New England Journal of Medicine, vol.347, issue.25, pp.1999-2009, 2002. ,
DOI : 10.1056/NEJMoa021967
Enzymatic Deficiency in Primaquine-Sensitive Erythrocytes, Science, vol.124, issue.3220, pp.484-485, 1956. ,
DOI : 10.1126/science.124.3220.484-a
Moderne Probleme der Humangenetik, pp.52-125, 1959. ,
DOI : 10.1007/978-3-642-94744-5_2
Study of glucose-6-phosphate dehydrogenase: History and molecular biology, American Journal of Hematology, vol.7, issue.1, pp.53-61, 1993. ,
DOI : 10.1002/ajh.2830420111
Pharmacogenetics of Drug Metabolising Enzymes: Importance for Personalised Medicine, Clinical Chemistry and Laboratory Medicine, vol.41, issue.4, pp.573-80, 2003. ,
DOI : 10.1515/CCLM.2003.087
La pharmacogénétique ou la promesse d'une médecine personnalisée : variations du métabolisme et du transport des médicaments, Ann Biol Clin, vol.62, pp.499-511, 2004. ,
Pharmacogenomics of adverse drug reactions: practical applications and perspectives, Pharmacogenomics, vol.10, issue.6, pp.961-970, 1993. ,
DOI : 10.2217/pgs.09.37
Antivitamines K??: pharmacologie et pharmacog??n??tique, EMC - Biologie m??dicale, vol.6, issue.2, 2011. ,
DOI : 10.1016/S2211-9698(11)71437-6
Regulation of Drug-Metabolizing Enzymes and Transporters in Infection, Inflammation, and Cancer, Drug Metabolism and Disposition, vol.36, issue.2, pp.205-221, 2008. ,
DOI : 10.1124/dmd.107.018747
Pharmacogenetics and pharmacogenomics, 2006. ,
MDR1 (ABCB1) polymorphisms: functional effects and clinical implications, Rev Invest Clin, vol.65, issue.5, pp.445-54, 2013. ,
The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study Nicolas Picard, Différents types d'études en pharmacogénétique, Pharmacogenet Genomics, 1922. ,
Bases mol??culaires de la susceptibilit?? aux x??nobiotiques : aspects m??taboliques., m??decine/sciences, vol.16, issue.10 ,
DOI : 10.4267/10608/1524
Clopidogrel???Drug Interactions, Journal of the American College of Cardiology, vol.57, issue.11, pp.1251-126, 2011. ,
DOI : 10.1016/j.jacc.2010.11.024
Cytochromes P450: xenobiotic metabolism,regulation and clinical importance; revue générale, Ann Biol Clin, vol.64, issue.6, pp.535-583, 2006. ,
Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment, Pharmacogenomics, vol.1, issue.2, pp.125-51, 2000. ,
DOI : 10.1517/14622416.1.2.125
CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin, Pharmacogenomics, vol.14, issue.2, pp.137-186, 2013. ,
Induction of phase I, II and III drug metabolism/transport by xenobiotics, Archives of Pharmacal Research, vol.182, issue.481, pp.249-68, 2005. ,
DOI : 10.1007/BF02977789
Regulation of Drug-Metabolizing Enzymes and Transporters in Infection, Inflammation, and Cancer, Drug Metabolism and Disposition, vol.36, issue.2, pp.205-221, 2008. ,
DOI : 10.1124/dmd.107.018747
Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice, Pharmacological Reviews, vol.58, issue.3, pp.521-90, 2006. ,
DOI : 10.1124/pr.58.3.6
Pharmacogenomics: out of the lab and into the community, Trends in Biotechnology, vol.19, issue.12, pp.519-523, 2001. ,
DOI : 10.1016/S0167-7799(01)01805-4
Genotype or phenotype: the definition of a pharmacogenetic polymorphism, Pharmacogenetics, vol.1, issue.2, pp.66-73, 1991. ,
DOI : 10.1097/00008571-199111000-00002
Development of analytical technology in pharmacogenetic research, Naunyn-Schmiedeberg's Archives of Pharmacology, vol.369, issue.1, pp.133-173, 2004. ,
DOI : 10.1007/s00210-003-0794-4
Interethnic differences of drug-metabolizing enzymes, Int. Journal of Clinical Pharmacology and Therapeutics, vol.38, issue.02, pp.61-69, 2000. ,
DOI : 10.5414/CPP38061
Practical recommendations for pharmacogenomics-based prescription, ESF-UB Conference onPharmacogenetics and Pharmacogenomics, pp.113-137, 2010. ,
DOI : 10.2217/pgs.10.147
Some Aspects of Genetic Polymorphism in the Biotransformation of Antidepressants, Th??rapie, vol.59, issue.1, 2004. ,
DOI : 10.2515/therapie:2004003
Cytochrome P450 mediated metabolism of diazepam in human and rat: involvement of human CYP2C in N-demethylation in the substrate concentration-dependent manner, Pharmacogenetics, vol.3, issue.6, 1993. ,
DOI : 10.1097/00008571-199312000-00003
The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans, Goldstein J A in The Journal of biological chemistry, 1994. ,
Weidolf Lars Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug metabolism and disposition: the biological fate of chemicals, 2004. ,
Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects, Blood, 2006. ,
Clinical importance of the CYP2C19*17 variant allele for voriconazole, Br J Clin Pharmacol, 2011. ,
Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs, Journal of biochemical and molecular toxicology, 1999. ,
AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents, Journal of the American College of Cardiology, 2010. ,